288 related articles for article (PubMed ID: 17875342)
1. Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites.
Okitsu SL; Boato F; Mueller MS; Li DB; Vogel D; Westerfeld N; Zurbriggen R; Robinson JA; Pluschke G
Peptides; 2007 Oct; 28(10):2051-60. PubMed ID: 17875342
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
Okitsu SL; Kienzl U; Moehle K; Silvie O; Peduzzi E; Mueller MS; Sauerwein RW; Matile H; Zurbriggen R; Mazier D; Robinson JA; Pluschke G
Chem Biol; 2007 May; 14(5):577-87. PubMed ID: 17524988
[TBL] [Abstract][Full Text] [Related]
3. Synthetic peptide immunogens eliciting antibodies to Plasmodium falciparum sporozoite and merozoite surface antigens in H-2b and H-2k mice.
Rzepczyk CM; Csurhes PA; Lord R; Matile H
J Immunol; 1990 Oct; 145(8):2691-6. PubMed ID: 2212657
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies.
Fox BA; Xing-Li P; Suzue K; Horii T; Bzik DJ
Exp Parasitol; 1997 Feb; 85(2):121-34. PubMed ID: 9030663
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibodies against the Plasmodium falciparum p126 antigen in non-responder H-2b and partial-responder H-2d mice using synthetic peptides.
Gilardeau Truffinet M; Bossus M; Camus D; Delplace P; Mazingue C; Diesis E; Tartar A; Moreau S; Gras-Masse H; Banic DM
Pept Res; 1996; 9(2):61-70. PubMed ID: 8738980
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro.
Locher CP; Tam LQ; Chang SP; McBride JS; Siddiqui WA
Exp Parasitol; 1996 Oct; 84(1):74-83. PubMed ID: 8888734
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
9. Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.
Tamborrini M; Mueller MS; Stoffel SA; Westerfeld N; Vogel D; Boato F; Zurbriggen R; Robinson JA; Pluschke G
Malar J; 2009 Dec; 8():314. PubMed ID: 20042100
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes.
Sakamoto H; Takeo S; Maier AG; Sattabongkot J; Cowman AF; Tsuboi T
Vaccine; 2012 Mar; 30(11):1972-80. PubMed ID: 22248820
[TBL] [Abstract][Full Text] [Related]
11. Plasmodium yoelii: experimental evidences for the conserved epitopes between mouse and human malaria parasite, Plasmodium falciparum.
Xu L; Pei X; Berzins K; Chaudhuri A
Exp Parasitol; 2007 Jul; 116(3):214-24. PubMed ID: 17336297
[TBL] [Abstract][Full Text] [Related]
12. A protective merozoite protein of Plasmodium falciparum shares an epitope with surface antigens of Paramecium.
Sehgal A; Singh NJ; Chakraborty T; Sharma S
Parasite Immunol; 2004 May; 26(5):219-27. PubMed ID: 15491471
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.
Kaushal DC; Kaushal NA; Narula A; Kumar N; Puri SK; Dutta S; Lanar DE
Indian J Biochem Biophys; 2007 Dec; 44(6):429-36. PubMed ID: 18320841
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
Teo WH; Nurul AA; Norazmi MN
Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
[TBL] [Abstract][Full Text] [Related]
17. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children.
Okech B; Mujuzi G; Ogwal A; Shirai H; Horii T; Egwang TG
Am J Trop Med Hyg; 2006 Feb; 74(2):191-7. PubMed ID: 16474069
[TBL] [Abstract][Full Text] [Related]
18. Two immunogenic peptide conjugates derived from P. falciparum MSA2 give rise to antibodies that crossreact with a nonhomologous 195-kDa malarial protein.
Lord R; Jones G; Saul A
Pept Res; 1993; 6(4):191-4. PubMed ID: 8400614
[TBL] [Abstract][Full Text] [Related]
19. High titer response against a malarial antigen depends on the flanking sequence of the immunizing peptide conjugate.
Jones GL; Gale J; Lord R; Edmundson HM; Saul A; Pye D
Pept Res; 1989; 2(4):282-5. PubMed ID: 2520766
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
